Figure 9. This figure compares the progression free survival (PFS) in patients with advanced metastatic PNETs treated with sunitinib in the SUN1111 trial (173) compared to everolimus in the RADIANT- 3 trial (177). While the PFS are similar, there are significant differences in the side effects; thus, choices need to be individualized.